Eyenovia Files Q1 2025 10-Q, Details Warrant Valuations
Ticker: HYPD · Form: 10-Q · Filed: May 19, 2025 · CIK: 1682639
| Field | Detail |
|---|---|
| Company | Eyenovia, INC. (HYPD) |
| Form Type | 10-Q |
| Filed Date | May 19, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, warrants
TL;DR
EYEN Q1 10-Q filed. Shows warrant valuation details. Financials look stable.
AI Summary
Eyenovia, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information, including retained earnings and additional paid-in capital as of March 31, 2025. It also references warrant valuation assumptions, including risk-free interest rates, price volatility, and expected terms, both before and after modifications.
Why It Matters
This filing provides insight into Eyenovia's financial health and the specific assumptions used in valuing its outstanding warrants, which can impact future share dilution.
Risk Assessment
Risk Level: medium — The filing contains standard financial disclosures, but the details on warrant valuation could indicate potential future dilution or changes in equity structure.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Marks the end of the financial period covered by the 10-Q.)
- 2025-05-19 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- EYENOVIA, INC. (company) — Filer of the 10-Q
- 20250331 (date) — End of the reporting period
- 20250519 (date) — Filing date
- 2834 (number) — Standard Industrial Classification for Pharmaceutical Preparations
- 471178401 (number) — EIN of Eyenovia, Inc.
FAQ
What were the key assumptions used in valuing Eyenovia's warrants before modification as of March 31, 2025?
The filing indicates that risk-free interest rate, price volatility, and expected term were key inputs for warrant valuation before modification.
What were the key assumptions used in valuing Eyenovia's warrants after modification as of March 31, 2025?
Similar to before modification, the filing lists risk-free interest rate, price volatility, and expected term as inputs for warrant valuation after modification.
What is Eyenovia, Inc.'s Standard Industrial Classification code?
Eyenovia, Inc. is classified under code 2834, which corresponds to Pharmaceutical Preparations.
What is the fiscal year end for Eyenovia, Inc.?
Eyenovia, Inc.'s fiscal year ends on December 31.
What are the reported values for Retained Earnings and Additional Paid-In Capital as of March 31, 2025?
The filing references us-gaap:RetainedEarningsMember and us-gaap:AdditionalPaidInCapitalMember for the date 2025-03-31, indicating these financial figures are reported.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 19, 2025 regarding EYENOVIA, INC. (HYPD).